RT Journal Article SR Electronic T1 Percutaneous Radiofrequency Ablation Therapy for Recurrent Hepatocellular Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5059 OP 5065 VO 32 IS 11 A1 HIROKI NISHIKAWA A1 YUKIO OSAKI A1 ERIKO IGUCHI A1 HARUHIKO TAKEDA A1 YOSHIAKI OHARA A1 AZUSA SAKAMOTO A1 KEIICHI HATAMARU A1 SUMIO SAITO A1 AKIHIRO NASU A1 RYUICHI KITA A1 TORU KIMURA YR 2012 UL http://ar.iiarjournals.org/content/32/11/5059.abstract AB Aim: To compare the overall survival (OS) in patients without recurrent hepatocellular carcinoma (HCC) after initial radiofrequency ablation (RFA) and in those with recurrence, treated with repeat-RFA. Patients and Methods: We compared OS between patients without recurrence (group A; n=150) and those with recurrence treated with repeat-RFA (group B; n=130). Results: One-, 3- and 5-year OS after initial RFA was 92.6%, 84.1% and 81.0%, respectively, in group A, and 99.0%, 84.1% and 61.8% in group B (p=0.296). There was no significant difference in OS between group A patients and patients with a single recurrent HCC (p=0.834). On multivariate analysis, serum albumin >3.5g/dl and first HCC recurrence, comprising of two or three nodules were significant predicting factors of poorer OS. Conclusion: Even if HCC recurs after initial RFA, survival comparable to that of patients without recurrence can be achieved in patients with a single recurrent tumor treated with repeat-RFA.